Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American Journal of Cardiology

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.amjcard.2010.05.031PMID 20854965
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database

  2009cited by this paper
• Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure.

  2009cited by this paper
• AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease

  2009cited by this paper
• Insulin resistance: a potential new target for therapy in patients with heart failure.

  2008cited by this paper
• Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

  2006cited by this paper
• Contraindications can damage your health—is metformin a case in point?

  2005cited by this paper
• Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study

  2005cited by this paper
• Metformin's contraindications should be contraindicated

  2005cited by this paper
• Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure.

  2005cited by this paper
• Metformin and heart failure: innocent until proven guilty.

  2005cited by this paper
• AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury.

  2004cited by this paper
• Metformin: An Update

  2002cited by this paper
• Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study

  2002cited by this paper
• Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

  2002cited by this paper
• Improved endothelial function with metformin in type 2 diabetes mellitus.

  2001cited by this paper
• Insulin resistance in chronic heart failure.

  2000cited by this paper
• Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.

  2000cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.

  1997cited by this paper
• The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register

  1997cited by this paper
• Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

  1995cited by this paper
• Insulin resistance in chronic heart failure.

  1994cited by this paper

• Predicting Short-Term Mortality in Elderly ICU Patients with Diabetes and Heart Failure: A Distributional Inference Framework

  2025cites this paper
• Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation

  2025cites this paper
• Clinical outcomes in type 2 diabetes patients with chronic heart failure treated with metformin: a meta-analysis

  2024cites this paper
• Metformin Treatment is Associated with Mortality in Patients with Type 2 Diabetes and Chronic Heart Failure in the Intensive Care Unit: A Retrospective Cohort Study

  2023cites this paper
• Analysis of Reports Sent to the Portuguese Pharmacovigilance System and Published Literature Regarding the Safety of Metformin in the Elderly

  2023influential citation
• Sulfonylureas as second line therapy for type 2 diabetes among veterans: Results from a National Longitudinal Cohort Study.

  2023cites this paper
• Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2023)

  2023cites this paper
• Amino acid homeostasis is a target of metformin therapy

  2023cites this paper
• Targeting cholesteryl ester accumulation in the heart improves cardiac insulin response.

  2022cites this paper
• Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF)

  2022cites this paper
• Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases

  2022cites this paper
• Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension

  2022cites this paper
• Looking for a medication that suppresses the expansion of the ascending aorta.

  2021cites this paper
• Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence

  2021cites this paper
• Adverse Effects of Metformin From Diabetes to COVID-19, Cancer, Neurodegenerative Diseases, and Aging: Is VDAC1 a Common Target?

  2021cites this paper
• Herzinsuffizienz bei Menschen mit Diabetes mellitus

  2021cites this paper
• Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications

  2021cites this paper
• Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas

  2021cites this paper
• Metformin: Up to Date.

  2020cites this paper
• Treatment and Prevention of Chronic Heart Failure in Elderly Patients with Type 2 Diabetes Mellitus. Part I. (Literature Review)

  2020cites this paper
• Use of Population-Based Health Informatics Research to Improve Care for Patients with Cardiovascular Diseases

  2020cites this paper
• Diabetes und Herzinsuffizienz

  2020cites this paper
• The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy

  2020cites this paper
• Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis

  2020cites this paper
• Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.

  2019cites this paper
• European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure

  2019cites this paper
• Leader in digital CPD for Southern African healthcare professionals Diabetes Earn up to 3 free CEUs

  2019cites this paper
• Diabetic Cardiomyopathy Pathophysiology and Update on Treatment

  2019cites this paper
• Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.

  2019cites this paper
• Diabetes und Herzinsuffizienz

  2019cites this paper
• Therapie der Herzinsuffizienz bei Diabetes

  2019cites this paper
• Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2019)

  2019cites this paper
• New advances in perioperative cardioprotection

  2019cites this paper
• Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America.

  2019cites this paper
• Heart failure and diabetes mellitus: insight into comorbidity

  2019cites this paper
• Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature

  2019cites this paper
• Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction

  2018cites this paper
• Diagnosis and the debatable issues of the treatment of heart failure with preserved ejection fraction

  2018cites this paper
• Revisiting the Diabetes-Heart Failure Connection

  2018cites this paper
• Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus.

  2018cites this paper
• Is metformin beneficial for heart failure in patients with type 2 diabetes?

  2017cites this paper
• Metformin in heart failure patients

  2017cites this paper
• Metformin and risk of long-term mortality following an admission for acute heart failure

  2017cites this paper
• Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease

  2017cites this paper
• Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing

  2017influential citation
• Diabetes Mellitus and Heart Failure.

  2017cites this paper
• Metformin; a review of its history and future: from lilac to longevity

  2017cites this paper
• Dyspnoe bei Diabetes und Herzinsuffizienz

  2017cites this paper
• Diabetes Mellitus and Heart Failure.

  2017cites this paper
• Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data.

  2017cites this paper
• Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure

  2017cites this paper
• Renoprotective Effects of Metformin

  2017cites this paper
• Herzinsuffizienz und Diabetes

  2017cites this paper
• Diabetes und Herzinsuffizienz

  2017cites this paper
• Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies

  2017cites this paper
• Therapeutische Strategien unter Berücksichtigung aktueller Studien

  2017cites this paper
• Contributory risk and Management of Comorbidities of Hypertension, obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure

  2016cites this paper
• Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz

  2016cites this paper
• Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status

  2016cites this paper
• Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association.

  2016cites this paper
• Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design

  2016cites this paper
• Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study

  2016cites this paper
• New peroral antidiabetic drugs and heart failure

  2016cites this paper
• What's new in heart failure in the patient with type 2 diabetes?

  2015cites this paper
• Sulfonylureas and meglitinides: insights into physiology and translational clinical utility

  2015cites this paper
• Metformin-associated lactic acidosis.

  2015cites this paper
• Addressing Limitations in Observational Studies of the Association Between Glucose-Lowering Medications and All-Cause Mortality: A Review

  2015cites this paper
• What's new in heart failure in the patient with type 2 diabetes?

  2015cites this paper
• Metformin-Associated Lactic Acidosis

  2015cites this paper
• Treatment of Hyperglycaemia in Type 2 Diabetic Patients in a Primary Care Population Database in a Mediterranean Area (Catalonia, Spain)

  2014cites this paper
• New-Onset Diabetes in Heart Failure Patients: A Complex Relationship with Clinical Implications

  2014cites this paper
• Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations

  2014influential citation
• Modulation of Cardiomyocyte and Hepatocyte Bioenergetics by Biguanides

  2014cites this paper
• Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34 000 Patients

  2013cites this paper
• The genetic determinants of cardiovascular disease in patients with type 2 diabetes

  2013cites this paper
• Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes.

  2013cites this paper
• Insulin: standard therapy following oral hypoglycaemic failure in type 2 diabetes?

  2013cites this paper
• Investigar en diabetes desde una base de datos de atención primaria: la experiencia del Sistema de Información para el Desarrollo de la Investigación en Atención Primaria (SIDIAP)

  2013cites this paper
• Cardiac metabolism in hypertrophy and heart failure: implications for therapy

  2013cites this paper
• Insulin resistance, chronic heart failure and potential treatment

  2013cites this paper
• Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies

  2013cites this paper
• Renoprotective effects of metformin

  2013cites this paper
• [Updating of the Brazilian guideline for chronic heart failure - 2012].

  2012cites this paper
• The impact of current and novel anti-diabetic therapies on cardiovascular risk.

  2012cites this paper
• Metformin and heart failure: never say never again

  2012influential citation
• Metformin Prevents the Development of Chronic Heart Failure in the SHHF Rat Model

  2012cites this paper
• The effect of metformin on insulin resistance and exercise parameters in patients with heart failure

  2012cites this paper
• Antihyperglycemic therapy in patients with type 2 diabetes mellitus and ischaemic heart disease: management during acute period of myocardial infarction and interventional procedures

  2012cites this paper
• Diabetes and Endocrinology Symposium: thinner, fitter, faster

  2012cites this paper
• Metformina — dlaczego jest preferowanym lekiem przeciwcukrzycowym? Metformin — why it is the drug of choice in diabetes?

  2011cites this paper
• Levels of evidence needed for changing indications, contraindications, and Food and Drug Administration labeling: the case of metformin.

  2011cites this paper
• Kardiale Endorganschäden bei Diabetes

  2011cites this paper
• Une complication mal connue du diabète : la cardiomyopathie diabétique

  2011cites this paper
• Changes in labelling for metformin use in patients with type 2 diabetes and heart failure: documented safety outweighs theoretical risks

  2011cites this paper
• Wrongfully accused: metformin use in heart failure

  2011cites this paper
• Diabetes mellitus und Herzinsuffizienz

  2011cites this paper
• Guidelines for the prevention , detection and management of chronic heart failure in Australia Updated October 2011

  2011cites this paper
• of metformin on mortality and cardiovascular events in patients with pre-existing

  year unknowncites this paper